Skip Navigation

European Heart Journal 2004 25(4):285-291; doi:10.1016/j.ehj.2003.11.017
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (53)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van der Meer, P.
Right arrow Articles by van Veldhuisen, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Meer, P.
Right arrow Articles by van Veldhuisen, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Erythropoietin in cardiovascular diseases

Peter van der Meera, Adriaan A. Voorsa, Erik Lipsica,b, Wiek H. van Gilstb,* and Dirk J. van Veldhuisena

a Department of Cardiology, University Hospital Groningen Groningen, The Netherlands
b Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherlands

* Corresponding author: Wiek H. van Gilst, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands. Tel.: +31-50-3632810; Fax:+31-50-3632812
E-mail address: w.h.van.gilst{at}med.rug.nl

Received 6 August 2003; revised 30 October 2003; accepted 27 November 2003

Abstract

Several studies showed that anaemia is commonly observed in patients with Chronic Heart Failure (CHF) and is associated with worsened symptoms and survival. When anaemia in these patients is treated with erythropoietin (EPO), a significant improvement in cardiac function and symptoms was observed. Although it was originally believed that EPO specifically acted on haematopoietical cells, recent evidence demonstrated several non-haematopoietical effects. Ischaemia/reperfusion experiments in rat heart and brain showed large infarct reduction when treated with EPO. Other effects of EPO are related to its pro-angiogenic effects on endothelial cells, which could be of potential value in patients with ischaemic heart disease. These preclinical findings suggest that EPO may have potential effects in cardiovascular disease beyond correction of haemoglobin levels.

Key Words: Erythropoietin • Apoptosis • Myocardial ischemia • Heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
P. van der Meer, J. L. Januzzi, and D. J. van Veldhuisen
Erythropoietin, haemoglobin, heart failure, and mortality: reply
Eur. Heart J., September 11, 2008; (2008) ehn400v1.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer
Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
I. B. Copland, E. M. Jolicoeur, M.-A. Gillis, J. Cuerquis, N. Eliopoulos, B. Annabi, A. Calderone, J.-F. Tanguay, A. Ducharme, and J. Galipeau
Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties
Cardiovasc Res, August 1, 2008; 79(3): 405 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. van der Meer, D. J. Lok, J. L. Januzzi, P. W. B.-A. de la Porte, E. Lipsic, J. van Wijngaarden, A. A. Voors, W. H. van Gilst, and D. J. van Veldhuisen
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients
Eur. Heart J., June 2, 2008; 29(12): 1510 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Joyeux-Faure
Cellular Protection by Erythropoietin: New Therapeutic Implications?
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal, D. J.A. Lok, S. M. Wasserman, N. Baker, D. Rosser, J. G.F. Cleland, and P. Ponikowski
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Eur. Heart J., September 2, 2007; 28(18): 2208 - 2216.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
N. F. Murphy and K. McDonald
Treatment of anaemia in chronic heart failure optimal approach still unclear
Eur. Heart J., September 2, 2007; 28(18): 2185 - 2187.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
B. D. Westenbrink, E. Lipsic, P. van der Meer, P. van der Harst, H. Oeseburg, G. J. Du Marchie Sarvaas, J. Koster, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, et al.
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization
Eur. Heart J., August 2, 2007; 28(16): 2018 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. D. Westenbrink, A. A. Voors, and D. J. van Veldhuisen
Is Anemia in Chronic Heart Failure Caused by Iron Deficiency?
J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2301 - 2302.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
F. Prunier, O. Pfister, L. Hadri, L. Liang, F. del Monte, R. Liao, and R. J. Hajjar
Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H522 - H529.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst
Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside
J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Similowski, A. Agusti, W. MacNee, and B. Schonhofer
The potential impact of anaemia of chronic disease in COPD
Eur. Respir. J., February 1, 2006; 27(2): 390 - 396.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. George, E. Goldstein, A. Abashidze, D. Wexler, S. Hamed, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth
Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner
Cardiovasc Res, November 1, 2005; 68(2): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. T. Vlagopoulos, H. Tighiouart, D. E. Weiner, J. Griffith, D. Pettitt, D. N. Salem, A. S. Levey, and M. J. Sarnak
Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3403 - 3410.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. van der Meer, E. Lipsic, B. D. Westenbrink, R. M.A. van de Wal, R. G. Schoemaker, E. Vellenga, D. J. van Veldhuisen, A. A. Voors, and W. H. van Gilst
Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure
Circulation, September 20, 2005; 112(12): 1743 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker
Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction
J. Am. Coll. Cardiol., July 5, 2005; 46(1): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. George, S. Patal, D. Wexler, A. Abashidze, H. Shmilovich, T. Barak, D. Sheps, and G. Keren
Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers
Arch Intern Med, June 13, 2005; 165(11): 1304 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Namiuchi, Y. Kagaya, J. Ohta, N. Shiba, M. Sugi, M. Oikawa, H. Kunii, H. Yamao, N. Komatsu, M. Yui, et al.
High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1406 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. van der Meer, A. A. Voors, E. Lipsic, T. D. J. Smilde, W. H. van Gilst, and D. J. van Veldhuisen
Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure
J. Am. Coll. Cardiol., July 7, 2004; 44(1): 63 - 67.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.